

Author's response to reviews

Title: Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Authors:

Rieke Alten (rieke.alten@schlosspark-klinik.de)
Juan Gomez-Reino (juan.gomez-reino.carnota@sergas.es)
Patrick Durez (Patrick.durez@ruma.ucl.ac.be)
Andre Beaulieu (ab5@videotron.ca)
Anthony Sebba (asebba@tampabay.rr.com)
Gerhard Krammer (gerhard.krammer@novartis.com)
Ralph Preiss (ralph.preiss@novartis.com)
Udayasankar Arulmani (udayasankar.arulmani@novartis.com)
Albert Widmer (albert.widmer@novartis.com)
Xavier Gitton (xavier.gitton@novartis.com)
Herbert Kellner (hk@prof-dr-kellner.de)

Version: 6 Date: 28 June 2011

Author's response to reviews:

Dear Editor, Authors' contributions are now corrected as requested

RA, PD, AB, GK, AW, XG contributed to the clinical trial design; JGR, AS, and HK were involved in the data collection; RA, AS, and HK were investigators; JGR, XG, GK, AW, RP, and UA were involved in the data analysis and data interpretation. All authors have participated in writing and reviewing and have approved the paper for publication.